Rebecca Schaefer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rebecca Schaefer has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Matthias Brendel
Department of Nuclear Medicine, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
4 shared publications - Lea Helena Kunze
Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany
3 shared publications - Simon Lindner
Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany
3 shared publications - Artem Zatcepin
Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany
2 shared publications - Giovanna Palumbo
Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
2 shared publications - Johannes Gnörich
Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany
2 shared publications
Latest Publications
- Open Access
- 21 March 2025
- Published by Elsevier in NeuroImage
- Vol. 310, 121165
Fibrillar amyloidosis and synaptic vesicle protein expression progress jointly in the cortex of a mouse model with β-amyloid pathology
- 21 March 2025
- Published by Elsevier in NeuroImage
- Vol. 310, 121165
Open AccessFibrillar amyloidosis and synaptic vesicle protein expression progress jointly in the cortex of a mouse model with β-amyloid pathology
- Open Access
- 30 January 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Design, Synthesis and Preclinical Evaluation of a brain-permeable PET Tracer for P2Y12R Imaging in the Brain
Microglia, the innate immune cells of the central nervous system (CNS), act as first responders in the context of brain injury or neurodegeneration. Their ability to switch between different neuroprotective and neurotoxic phenotypes, plays a central role in maintaining brain homeostasis. Recently, the P2Y12 receptor (P2Y12R) has been identified as a promising molecular biomarker for microglia, as its expression level is directly dependent on microglia phenotype and function. A decline in P2Y12R expression is indicative of damage, microglial malfunction or chronic neuroinflammation, as observed in neurodegenerative diseases such as Alzheimer's disease (AD). Novel therapeutic strategies aiming to modulate microglia phenotypes directly depend on matching diagnostic tools for success control. Accordingly, a suitable P2Y12R positron emission tomography (PET) tracer is hypothesised to provide valuable in vivo information regarding microglia activation within the CNS. However, P2Y12R PET tracers with sufficient brain retention for neuroimaging have not been reported so far. Herein, we report the first brain-permeable P2Y12R PET tracer for in vivo imaging of P2Y12R-positive microglia. Nicotinate [18F]12 exhibited nanomolar affinity for the target receptor and favourable in silico parameters. Tracer specificity was proven by in vitro autoradiography (ARG) and brain uptake was confirmed by PET imaging in wild-type (WT) mice and ex vivo biodistribution. Ex vivo metabolite analysis indicated the exclusive presence of intact tracer in the mouse brain, with no evidence of any radio-metabolites. The tracer showed a reduced uptake in microglia-depleted mice after PLX-5622 diet, in comparison to WT and Trem2 knock-out (Trem2-/-) mice. Ex vivo immunohistochemistry (IHC) results and PET data revealed a strong correlation between microglia, P2Y12R expression levels and tracer uptake giving strong evidence that P2Y12 PET signal reflects P2Y12R binding. This novel tracer represents an important step forward in P2Y12 PET imaging in the context of neuroinflammation.
- 30 January 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDesign, Synthesis and Preclinical Evaluation of a brain-permeable PET Tracer for P2Y12R Imaging in the Brain
Microglia, the innate immune cells of the central nervous system (CNS), act as first responders in the context of brain injury or neurodegeneration. Their ability to switch between different neuroprotective and neurotoxic phenotypes, plays a central role in maintaining brain homeostasis. Recently, the P2Y12 receptor (P2Y12R) has been identified as a promising molecular biomarker for microglia, as its expression level is directly dependent on microglia phenotype and function. A decline in P2Y12R expression is indicative of damage, microglial malfunction or chronic neuroinflammation, as observed in neurodegenerative diseases such as Alzheimer's disease (AD). Novel therapeutic strategies aiming to modulate microglia phenotypes directly depend on matching diagnostic tools for success control. Accordingly, a suitable P2Y12R positron emission tomography (PET) tracer is hypothesised to provide valuable in vivo information regarding microglia activation within the CNS. However, P2Y12R PET tracers with sufficient brain retention for neuroimaging have not been reported so far. Herein, we report the first brain-permeable P2Y12R PET tracer for in vivo imaging of P2Y12R-positive microglia. Nicotinate [18F]12 exhibited nanomolar affinity for the target receptor and favourable in silico parameters. Tracer specificity was proven by in vitro autoradiography (ARG) and brain uptake was confirmed by PET imaging in wild-type (WT) mice and ex vivo biodistribution. Ex vivo metabolite analysis indicated the exclusive presence of intact tracer in the mouse brain, with no evidence of any radio-metabolites. The tracer showed a reduced uptake in microglia-depleted mice after PLX-5622 diet, in comparison to WT and Trem2 knock-out (Trem2-/-) mice. Ex vivo immunohistochemistry (IHC) results and PET data revealed a strong correlation between microglia, P2Y12R expression levels and tracer uptake giving strong evidence that P2Y12 PET signal reflects P2Y12R binding. This novel tracer represents an important step forward in P2Y12 PET imaging in the context of neuroinflammation.
- Open Access
- 25 September 2024
- Published by Elsevier in NeuroImage
- Vol. 300, 120860
Astroglial glucose uptake determines brain FDG-PET alterations and metabolic connectivity during healthy aging in mice
- 25 September 2024
- Published by Elsevier in NeuroImage
- Vol. 300, 120860
Open AccessAstroglial glucose uptake determines brain FDG-PET alterations and metabolic connectivity during healthy aging in mice
- Open Access
- 27 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (43) , eadi8986
Deciphering sources of PET signals in the tumor microenvironment of glioblastoma at cellular resolution
Various cellular sources hamper interpretation of positron emission tomography (PET) biomarkers in the tumor microenvironment (TME). We developed an approach of immunomagnetic cell sorting after in vivo radiotracer injection (scRadiotracing) with three-dimensional (3D) histology to dissect the cellular allocation of PET signals in the TME. In mice with implanted glioblastoma, translocator protein (TSPO) radiotracer uptake per tumor cell was higher compared to tumor-associated microglia/macrophages (TAMs), validated by protein levels. Translation of in vitro scRadiotracing to patients with glioma immediately after tumor resection confirmed higher single-cell TSPO tracer uptake of tumor cells compared to immune cells. Across species, cellular radiotracer uptake explained the heterogeneity of individual TSPO-PET signals. In consideration of cellular tracer uptake and cell type abundance, tumor cells were the main contributor to TSPO enrichment in glioblastoma; however, proteomics identified potential PET targets highly specific for TAMs. Combining cellular tracer uptake measures with 3D histology facilitates precise allocation of PET signals and serves to validate emerging novel TAM-specific radioligands.
- 27 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (43) , eadi8986
Open AccessDeciphering sources of PET signals in the tumor microenvironment of glioblastoma at cellular resolution
Various cellular sources hamper interpretation of positron emission tomography (PET) biomarkers in the tumor microenvironment (TME). We developed an approach of immunomagnetic cell sorting after in vivo radiotracer injection (scRadiotracing) with three-dimensional (3D) histology to dissect the cellular allocation of PET signals in the TME. In mice with implanted glioblastoma, translocator protein (TSPO) radiotracer uptake per tumor cell was higher compared to tumor-associated microglia/macrophages (TAMs), validated by protein levels. Translation of in vitro scRadiotracing to patients with glioma immediately after tumor resection confirmed higher single-cell TSPO tracer uptake of tumor cells compared to immune cells. Across species, cellular radiotracer uptake explained the heterogeneity of individual TSPO-PET signals. In consideration of cellular tracer uptake and cell type abundance, tumor cells were the main contributor to TSPO enrichment in glioblastoma; however, proteomics identified potential PET targets highly specific for TAMs. Combining cellular tracer uptake measures with 3D histology facilitates precise allocation of PET signals and serves to validate emerging novel TAM-specific radioligands.